3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
74
Thoracic
24
Genitourinary
23
Gynecologic
20
Dermatologic
19
Head & Neck
18
Breast
16
Sarcoma
5
Lymphoid
3
Other solid neoplasm
2
CNS
1
Conditions
Glioblastoma
40
Brain Neoplasms
34
Melanoma
15
Glioma
13
Carcinoma, Non-Small-Cell Lung
9
Gliosarcoma
7
Neoplasms
6
Carcinoma, Renal Cell
6
Stomach Neoplasms
5
Ovarian Neoplasms
4
Meningioma
4
Lung Neoplasms
4
Esophageal Neoplasms
4
Colorectal Neoplasms
4
Breast Neoplasms
4
Astrocytoma
4
Uterine Cervical Neoplasms
3
Triple Negative Breast Neoplasms
3
Sarcoma
3
Recurrence
3
Central Nervous System Neoplasms
3
Uveal Melanoma
2
Turcot syndrome
2
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Pancreatic Neoplasms
2
Neuroblastoma
2
Neoplasms, Germ Cell and Embryonal
2
Neoplasm Metastasis
2
Interventions
Nivolumab
4
Magnetic Resonance Spectroscopy
4
fludarabine
3
Fluorodeoxyglucose F18
3
Cyclophosphamide
3
Cisplatin
3
ulixertinib
2
sargramostim
2
X-Rays
2
Trastuzumab
2
Sunitinib
2
Stem Cell Transplantation
2
Specimen Handling
2
Sirolimus
2
Oxaliplatin
2
Melphalan
2
Leucovorin
2
FAPI-46
2
Erlotinib Hydrochloride
2
Cryosurgery
2
Crizotinib
2
Capecitabine
2
Busulfan
2
Bevacizumab
2
trifluridine tipiracil drug combination
1
trastuzumab biosimilar HLX02
1
trametinib
1
tipifarnib
1
sapanisertib
1
sacituzumab govitecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Hepatocellular
×
pembrolizumab
×
CNS
×
Clear all
NCT04187872
2023-12-27
TORCH
University of Florida
Phase 1
Terminated
10 enrolled